WO2020144355A3 - Peptides immunogènes issus de la nucléoprotéine du virus ebola zaïre - Google Patents

Peptides immunogènes issus de la nucléoprotéine du virus ebola zaïre Download PDF

Info

Publication number
WO2020144355A3
WO2020144355A3 PCT/EP2020/050587 EP2020050587W WO2020144355A3 WO 2020144355 A3 WO2020144355 A3 WO 2020144355A3 EP 2020050587 W EP2020050587 W EP 2020050587W WO 2020144355 A3 WO2020144355 A3 WO 2020144355A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleoprotein
sequences
virus
ebola
ebola virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2020/050587
Other languages
English (en)
Other versions
WO2020144355A2 (fr
Inventor
Bernard Maillere
Yann GALLAIS
Evelyne CORREIA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique CEA, Commissariat a lEnergie Atomique et aux Energies Alternatives CEA filed Critical Commissariat a lEnergie Atomique CEA
Publication of WO2020144355A2 publication Critical patent/WO2020144355A2/fr
Publication of WO2020144355A3 publication Critical patent/WO2020144355A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une composition immunogène ou vaccinale contre le virus Ebola, comprenant au moins un premier peptide immunogène issu de la nucléoprotéine (NP) du virus Ebola Zaïre, qui est capable d'induire une réponse en lymphocytes T CD4+ humains spécifiques du virus Ebola, ledit peptide étant sélectionné dans le groupe constitué par les séquences SEQ ID NO : 2 à 24 et les séquences comprenant au plus trois mutations d'acides aminés dans lesdites séquences ou une délétion d'au plus trois acides aminés aux extrémités desdites séquences. L'invention concerne également l'utilisation de ladite composition comme vaccin préventif contre le virus Ebola et comme réactif pour l'immunomonitorage de la réponse cellulaire contre le virus Ebola.
PCT/EP2020/050587 2019-01-11 2020-01-10 Peptides immunogènes issus de la nucléoprotéine du virus ebola zaïre Ceased WO2020144355A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1900281A FR3091651A1 (fr) 2019-01-11 2019-01-11 Peptides immunogènes issus de la nucléoprotéine du virus ebola zaïre
FR1900281 2019-01-11

Publications (2)

Publication Number Publication Date
WO2020144355A2 WO2020144355A2 (fr) 2020-07-16
WO2020144355A3 true WO2020144355A3 (fr) 2020-09-03

Family

ID=67383855

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2020/050587 Ceased WO2020144355A2 (fr) 2019-01-11 2020-01-10 Peptides immunogènes issus de la nucléoprotéine du virus ebola zaïre

Country Status (2)

Country Link
FR (1) FR3091651A1 (fr)
WO (1) WO2020144355A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061504A2 (fr) * 2014-10-17 2016-04-21 The University Of Chicago Anticorps de recombinaison qui reconnaissent les domaines c-terminal de la nucléoprotéine du virus ebola

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
FR2776926B1 (fr) 1998-04-07 2003-10-24 Inst Nat Sante Rech Med Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination
FR2788698B1 (fr) 1999-01-27 2001-03-30 Commissariat Energie Atomique Peptides et proteines aptes a desensibiliser les sujets allergiques au venin d'abeille et compositions les contenant

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061504A2 (fr) * 2014-10-17 2016-04-21 The University Of Chicago Anticorps de recombinaison qui reconnaissent les domaines c-terminal de la nucléoprotéine du virus ebola

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CALLIE E. BOUNDS ET AL: "An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice", HUMAN VACCINES AND IMMUNOTHERAPEUTICS, vol. 13, no. 12, 2 December 2017 (2017-12-02), US, pages 2824 - 2836, XP055640130, ISSN: 2164-5515, DOI: 10.1080/21645515.2017.1329788 *
IVAN DIMITROV ET AL: "MHC Class II Binding Prediction-A Little Help from a Friend", JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, vol. 14, no. 2, 1 January 2010 (2010-01-01), pages 121 - 8, XP055227387, ISSN: 1110-7243, DOI: 10.1155/2010/705821 *
JAIN SAHIL ET AL: "Conserved peptide vaccine candidates containing multiple Ebola nucleoprotein epitopes display interactions with diverse HLA molecules", MEDICAL MICROBIOLOGY AND IMMUNOLOGY, SPRINGER, DE, vol. 208, no. 2, 21 February 2019 (2019-02-21), pages 227 - 238, XP036747742, ISSN: 0300-8584, [retrieved on 20190221], DOI: 10.1007/S00430-019-00584-Y *
KELLY L. WARFIELD ET AL: "Ebola Virus-Like Particle-Based Vaccine Protects Nonhuman Primates against Lethal Ebola Virus Challenge", JOURNAL OF INFECTIOUS DISEASES. JID, vol. 196, no. s2, 15 November 2007 (2007-11-15), US, pages S430 - S437, XP055239478, ISSN: 0022-1899, DOI: 10.1086/520583 *
M. SAIJO ET AL: "Enzyme-Linked Immunosorbent Assays for Detection of Antibodies to Ebola and Marburg Viruses Using Recombinant Nucleoproteins", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 39, no. 1, 1 January 2001 (2001-01-01), US, pages 1 - 7, XP055679514, ISSN: 0095-1137, DOI: 10.1128/JCM.39.1.1-7.2001 *
MARYAM HEMMATI, EHSAN RAOUFI AND HOSSEIN FALLAHI: "Predicting Candidate Epitopes on Ebola Virus for Possible Vaccine Development", 20 December 2017 (2017-12-20), pages 55 - 74, XP002795655, Retrieved from the Internet <URL:https://www.intechopen.com/books/advances-in-ebola-control/predicting-candidate-epitopes-on-ebola-virus-for-possible-vaccine-development> [retrieved on 20191114] *
SANCHEZ A ET AL: "The nucleoprotein gene of ebola virus: Cloning, sequencing, and in vitro expression", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 170, no. 1, 1 May 1989 (1989-05-01), pages 81 - 91, XP026424691, ISSN: 0042-6822, [retrieved on 19890501] *
SAORI SAKABE ET AL: "Analysis of CD8 + T cell response during the 2013-2016 Ebola epidemic in West Africa", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 115, no. 32, 7 August 2018 (2018-08-07), pages E7578 - E7586, XP055595456, ISSN: 0027-8424, DOI: 10.1073/pnas.1806200115 *
SINA BAVARI ET AL: "Lipid Raft Microdomains : A Gateway for Compartmentalized Trafficking of Ebola and Marburg Viruses", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 195, no. 5, 4 March 2002 (2002-03-04), US, pages 593 - 602, XP055475165, ISSN: 0022-1007, DOI: 10.1084/jem.20011500 *

Also Published As

Publication number Publication date
WO2020144355A2 (fr) 2020-07-16
FR3091651A1 (fr) 2020-07-17

Similar Documents

Publication Publication Date Title
EP4467650A3 (fr) Protéines d&#39;échafaudage
PE20210376A1 (es) Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
NZ570553A (en) Immunogenic peptide sequences from influenza A and B and uses thereof for vaccines
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
WO2021198706A3 (fr) Vaccins contre le coronavirus
MX2011011960A (es) Peptidos penetradores de celulas.
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
PE20140986A1 (es) Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae
MX358725B (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
DE602005020165D1 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
NZ708990A (en) Method for activating helper t cell
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
WO2018224573A8 (fr) Virus de la rougeole recombinant exprimant des protéines du virus zika et leurs applications
MX2009007261A (es) Vacuna de peptido foxp3.
NZ586074A (en) LCLRP peptides, constructs and uses thereof
PH12018500468A1 (en) Fusion protein
DK1904529T3 (da) Anvendelse af Stefin A som et scaffoldprotein
MX2010005816A (es) Epítopos de péptido de stat3.
ATE551353T1 (de) Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten
WO2019123018A3 (fr) Vaccin contre lassa
WO2012162637A3 (fr) Adjuvants pour vaccins à partir de peptides auto-assemblés
WO2020144355A3 (fr) Peptides immunogènes issus de la nucléoprotéine du virus ebola zaïre

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20700211

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20700211

Country of ref document: EP

Kind code of ref document: A2